A new trading day began on Friday, with Prelude Therapeutics Inc (NASDAQ: PRLD) stock price up 46.40% from the previous day of trading, before settling in for the closing price of $0.89. PRLD’s price has ranged from $0.80 to $6.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 12.13%. With a float of $21.88 million, this company’s outstanding shares have now reached $42.18 million.
The firm has a total of 128 workers. Let’s measure their productivity. In terms of profitability, gross margin is 81.18%, operating margin of -2230.11%, and the pretax margin is -2047.28%.
Prelude Therapeutics Inc (PRLD) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Prelude Therapeutics Inc is 60.25%, while institutional ownership is 35.27%. The most recent insider transaction that took place on Dec 19 ’24, was worth 22,638. In this transaction CLO, Interim CFO, Corp Sec. of this company bought 25,000 shares at a rate of $0.91, taking the stock ownership to the 27,400 shares. Before that another transaction happened on Dec 18 ’24, when Company’s CEO bought 100,000 for $0.93, making the entire transaction worth $93,210. This insider now owns 1,167,275 shares in total.
Prelude Therapeutics Inc (PRLD) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.10% during the next five years compared to -43.14% drop over the previous five years of trading.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Here are Prelude Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 34.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Analysing the last 5-days average volume posted by the [Prelude Therapeutics Inc, PRLD], we can find that recorded value of 1.44 million was better than the volume posted last year of 0.21 million. As of the previous 9 days, the stock’s Stochastic %D was 45.80%. Additionally, its Average True Range was 0.14.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 8.39%, which indicates a significant decrease from 77.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 182.82% in the past 14 days, which was higher than the 144.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2289, while its 200-day Moving Average is $3.4953. Now, the first resistance to watch is $1.5209. This is followed by the second major resistance level at $1.7417. The third major resistance level sits at $2.0335. If the price goes on to break the first support level at $1.0083, it is likely to go to the next support level at $0.7165. Should the price break the second support level, the third support level stands at $0.4957.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
With a market capitalization of 104.75 million, the company has a total of 55,035K Shares Outstanding. Currently, annual sales are 0 K while annual income is -121,830 K. The company’s previous quarter sales were 3,000 K while its latest quarter income was -32,270 K.
